Skip to main content
. 2020 May 5;9(5):44. doi: 10.1038/s41389-020-0228-x

Fig. 7. Model depicting the mechanism of HAT1 loss-induced BRAFi resistance.

Fig. 7

One of the mechanisms by which loss of HAT1 drives acquired BRAFi resistance is via IGF1R-dependent activation of MAPK signaling pathway, and the pharmacological targeting of IGF1R or ERK1/2 restores the sensitivity of melanoma cells with reduced HAT1 expression levels to BRAFi.